Lilly Launches Mounjaro in India for Obesity and Type 2 Diabetes Treatment

Eli Lilly and Company launched Mounjaro in single-dose vial presentation following the marketing authorization from the Central Drugs Standard Control Organization (CDSCO). It is a first-of-its-kind treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.
 
Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. Mounjaro is also indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.
 
“The dual burden of obesity and type 2 diabetes is rapidly emerging as a major public health challenge in India. Lilly is committed to collaborating with the government and industry to promote awareness and improve the prevention and management of these diseases,” said Winselow Tucker, president and general manager, Lilly India.
 
“Our mission to making life better for people living with obesity and diabetes in India is reflected in our efforts to accelerate the introduction of innovative medicines. The launch of Mounjaro demonstrates our ongoing support to this mission and our shared vision of a healthier nation,” he said.
 
Tirzepatide was evaluated in two robust global clinical development programmes: the SURMOUNT - 1 trials for chronic weight management and the SURPASS trials for type 2 diabetes.
 
“Obesity and diabetes are recognized as serious conditions linked to various life-limiting health complications, making effective and sustained treatment critical. We are thrilled to introduce Mounjaro in India to address these unmet medical needs. Mounjaro may offer a new approach to metabolic health management, providing healthcare providers with an innovative option to treat these diseases,” said Dr. Manish Mistry, senior medical director, Lilly India.
 
Once-a-weekly, prescription-based medicine, Mounjaro is a single molecule that selectively binds to and activates both GIP and GLP-1 receptors, which are natural incretin hormones. In a glucose-dependent manner, Mounjaro improves first phase and second phase insulin secretion, and reduces glucagon levels; it also improves insulin sensitivity and delays gastric emptying. GIP receptors and GLP-1 receptors are both expressed in important areas of the brain that regulate appetite. Mounjaro reduces food intake, body weight, and decreases fat mass by regulating appetite; moreover, Mounjaro has been demonstrated to regulate lipid utilization. Mounjaro (tirzepatide) has already had a tremendous impact on millions of people living with type 2 diabetes and obesity, respectively, stated the company note.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!